Drapkin Kimberlee C Form 3 Jounce Therapeutics / Kimberlee C Drapkin ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Drapkin Kimberlee C

(Last) (First) (Middle)

C/O JOUNCE THERAPEUTICS, INC.

1030 MASSACHUSETTS AVENUE

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/26/2017

3. Issuer Name and Ticker or Trading Symbol
Jounce Therapeutics, Inc. [ JNCE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CFO and Treasurer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6,775(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	01/27/2024	Common Stock	6,775	0.48	D
Stock Option (Right to Buy)	(3)	01/12/2025	Common Stock	6,775	0.74	D
Stock Option (Right to Buy)	(4)	08/25/2025	Common Stock	226,214	2.36	D
Stock Option (Right to Buy)	(5)	12/08/2025	Common Stock	8,130	4.02	D
Stock Option (Right to Buy)	(6)	10/24/2026	Common Stock	77,235	9.56	D

Explanation of Responses:

1. The shares were granted pursuant to a restricted stock grant on February 6, 2013, and vested in 12 monthly installments from October 9, 2012.

2. The option shares vested and became exercisable in 12 monthly installments from October 9, 2013.

3. The option shares vested and became exercisable in 12 monthly installments from October 9, 2014.

4. 25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter.

5. The option shares vest and become exercisable in 16 quarterly installments from December 9, 2015.

6. The option shares vest and become exercisable in 16 quarterly installments from October 24, 2016.

Remarks:

Exhibit 24.1: Limited Power of Attorney

	/s/ Kimberlee C. Drapkin	01/26/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.